Adjustment of insulin Degludec to Reduce post-Exercise (nocturnal) hypoglycaeMia in people with diabetes – the ADREM study
Latest Information Update: 09 Mar 2023
At a glance
- Drugs Insulin degludec (Primary)
- Indications Type 1 diabetes mellitus
- Focus Therapeutic Use
- Acronyms ADREM
Most Recent Events
- 07 Mar 2023 Results published in the Diabetologia
- 23 Sep 2022 Primary endpoint (Time spent in hypoglycaemic range (i.e. glucose 3.8 mmol/l) during the night (00:00 to 05:59h) following the exercise day measured by continuous glucose monitoring.) has been met, as per results presented at the 58th Annual Meeting of the European Association for the Study of Diabetes.
- 23 Sep 2022 Results assessing three degludec dosing regimens after a 45-minute exercise test on a bicycle ergometer, followed by blinded continuous glucosemonitoring for 6 days, presented at the 58th Annual Meeting of the European Association for the Study of Diabetes.